Download full-text PDF

Source

Publication Analysis

Top Keywords

[the 1st
4
1st psychopedagogical
4
psychopedagogical clinic
4
clinic northern
4
northern region]
4
[the
1
psychopedagogical
1
clinic
1
northern
1
region]
1

Similar Publications

Background And Aim: Although the relationship between selenium and metabolic syndrome (MetS) was previously investigated, the findings were inconsistent. Therefore, we performed a systematic review and dose-response meta-analysis to summarize the association between blood selenium and MetS in adults.

Methods: A comprehensive search was conducted in Medline (PubMed), ISI Web of Science, Scopus, and motor engineering of Google Scholar up to October 1st, 2024.

View Article and Find Full Text PDF

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives.

Cancer Manag Res

January 2025

Department of Gynecologic Oncology, University of California, Irvine-Medical Center, Orange, California, USA.

Endometrial cancer (EC) is the most common gynecologic cancer in developed nations with reported 420,368 new cases worldwide in 2022 and resulting in 97,723 deaths that year; it is also one of the few cancers with expected increases in incidence and mortality, which are expected to increase by 50% and 70%, respectively, by 2045. The mortality from EC can largely be attributed to the advanced stage and recurrent cases. Over the past decade, the standard of care for treatment of primary advanced stage and recurrent EC has been chemotherapy, resulting in a median overall survival (OS) of less than 3 years.

View Article and Find Full Text PDF

Unlabelled: A recently discovered koinobiont parasitoid species, Shimbori, 2023, proved to be a promising biological control agent for larvae of (Walker, 1858), (Stoll, 1782), and (J.E. Smith, 1797), all well-known pests that cause critical damage to soybean and corn crops.

View Article and Find Full Text PDF

Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy.

Methods: This retrospective real-world study enrolled adult patients with diabetes taking Sema-o, with at least one follow-up (from February 2022 till October 2023).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!